PAVmed

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. The company's products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. PAVmed was founded on June 26, 2014 and is headquartered in New York, NY.

Lucid Diagnostics

Advocated stronger transparency and predictability, and inclusion of diagnostics, in federal proposals to improve equitable access to innovative lifesaving technologies Highlighted EsoGuard's life-saving potential, and unprecedented early detection results of a recently posted NCI-supported EsoGuard study NEW YORK , July 19, 2023 /PRNewswire/ -- PAVmed Inc.  (NASDAQ: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company, announced that PAVmed and Lucid's Chairman and Chief Executive Officer, Lishan Aklog, M.D, testified yesterday at the U.S. House of Representatives Energy and Commerce Committee, Subcommittee on Health, hearing entitled "Innovation Saves Lives: Evaluating Medicare Coverage Pathways for Innovative Drugs, Medical Devices, and Technology". Dr. Aklog, who serves on the Executive Committee of the Board of Directors of AdvaMed, the world's largest medical technology association, and as the inaugural chair of its committee focused on health equity, vigorously advocated for stronger transparency and predictability, and the inclusion of diagnostics, in two related federal proposals to improve equitable access to innovative technologies such as Lucid's EsoGuard® Esophageal DNA Test ("EsoGuard)—the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 (H.R.

PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Coverage

NEW YORK , June 28, 2023 /PRNewswire/ -- PAVmed Inc.  (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it received a written notice (the "Extension Notice") from the Nasdaq Stock Market LLC ("Nasdaq") granting the Company a 180-day extension to regain compliance with Nasdaq's $1.00 minimum bid price requirement as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Rule"). The Company was first notified by Nasdaq on December 29, 2022, and originally was given until June 27, 2023, to regain compliance.

PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

NEW YORK, June 14, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, announced today that the Company's Chairman and Chief Executive Officer, Lishan Aklog, M.D., has been invited to participate in the Healthcare Virtual Conference, presented by Maxim Group LLC. The conference is being held virtually on June 20-22, 2023.

PAVmed to Participate in Healthcare Virtual Conference Presented by Maxim Group LLC

First esophageal precancer detection event utilizing an EsoGuard mobile test unit to be hosted today by Florida Digestive Health Specialists in Sarasota, Florida NEW YORK , June 5, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced the launch of its first EsoGuard® #CheckYourFoodTube Mobile Test Unit serving patients and practices in the Greater Central Florida area. Florida Digestive Health Specialists ("FDHS"), Florida's largest gastroenterology network, will co-host the inaugural precancer detection event at the Gastroenterology Associates of Sarasota offices in Sarasota, Florida under the direction of Dr. Scott Corbett, Chief of Gastroenterology at Sarasota Memorial Hospital.

Lucid Diagnostics Launches First EsoGuard® Mobile Test Unit

NEW YORK , June 2, 2023 /PRNewswire/ -- PAVmed Inc.  (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced its participation as a founding member of CancerX – a public-private partnership co-hosted by Moffitt Cancer Center and the Digital Medicine Society ("DiMe"), alongside the Office for the National Coordinator for Health Information Technology ("ONC") and Office of the Assistant Secretary for Health ("OASH"). President Biden and Dr. Jill Biden announced CancerX in February 2023 as part of The White House's national Cancer Moonshot initiative to serve as a national accelerator to boost innovation in the fight against cancer.

PAVmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot's CancerX Partnership as Founding Member

Alzamend Neuro

Biora Therapeutics Inc

Developing groundbreaking drugs and devices entails high costs, uncertain regulatory approval, and lucrative revenues. Those factors and more culminate to create a sector filled with dozens of biotech stocks that have 10X potential, or better.

3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024

PAVmed Inc. (NASDAQ:PAVM ) Q1 2023 Earnings Conference Call May 17, 2023 8:30 AM ET Company Participants Lishan Aklog - Chairman, Chief Executive Officer Dennis McGrath - Executive Vice President, Chief Financial Officer Michael Parks - Vice President, Investor Relations Conference Call Participants Ross Osborn - Cantor Fitzgerald Anthony Vendetti - Maxim Group Ed Woo - Ascendiant Capital Operator Welcome to the PAVmed business update and first quarter 2023 financial results conference call. At this time, all participants are in a listen-only mode.

PAVmed (PAVM) Q1 2023 Earnings Call Transcript

EsoGuard® test volume gains momentum as Lucid expands high-volume testing events PAVmed appoints President for Veris Health and expands commercial footprint Conference call and webcast to be held tomorrow, May 17 th at 8:30 AM EST NEW YORK , May 16, 2023 /PRNewswire/ -- PAVmed Inc.  (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three months ended March 31, 2023. Conference Call and Webcast The webcast will take place on Wednesday, May 17, 2023, at 8:30 AM and will be accessible in the investor relations section of the Company's website at pavmed.com.

PAVmed Provides Business Update and First Quarter Financial Results

EsoGuard® test volume increases 57 percent sequentially and 245 percent year-on-year Conference call and webcast to be held tomorrow, May 16 th at 8:30 AM EST NEW YORK , May 15, 2023 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today provided a business update for the Company and presented financial results for the three months ended March 31, 2023. Conference Call and Webcast The webcast will take place on Tuesday, May 16, 2023, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.

Lucid Diagnostics Provides Business Update and First Quarter Financial Results

EsoGuard® continues to demonstrate excellent esophageal precancer and cancer detection performance, including in most prevalent and challenging precancer subgroup—short segment non-dysplastic Barrett's Esophagus EsoCheck® cell collection performed with 98 percent technical success and high DNA yields in real-world study of 1483 patients NEW YORK , May 11, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced findings from two clinical studies of its EsoGuard® Esophageal DNA Test and EsoCheck® Cell Collection Device, presented at this week's Digestive Disease Week (DDW) 2023 conference—the world's premier meeting for digestive disease professionals. "We are excited that Lucid had a strong presence and it's technologies garnered widespread interest at this year's DDW conference," said Suman Verma, M.D.

Lucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference

NEW YORK, May 5, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Wednesday, May 17, 2023, at 8:30 AM EST. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's first-quarter 2023 financial results.

PAVmed to Hold a Business Update Conference Call and Webcast on May 17, 2023

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , May 5, 2023 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, May 16, 2023, at 8:30 AM EST. During the call,  Lishan Aklog, M.D.

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 16, 2023

NEW YORK, April 25, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced the appointment of Gary Manning to the newly created position of President, Veris Health. Mr. Manning reports directly to Lishan Aklog, M.D., PAVmed's Chairman & Chief Executive Officer and Veris' Executive Chairman.

PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President

Company presenting at highly influential HIMSS23 Global Health Conference, today, April 19, 2023 from 11:30 a.m. to 12:30 p.m.

PAVmed Digital Health Subsidiary, Veris Health, to Present Comprehensive Meta-analysis on Impact of Remote Patient Monitoring in Oncology at HIMSS

Foundational LCD, to be effective May 14, 2023, incorporates key feedback to 2022 draft, including updated guidelines recommending non-endoscopic biomarker testing Lucid positioned to submit EsoGuard for Technical Assessment and coverage under foundational LCD when sufficient clinical utility data available later this year NEW YORK , March 31, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), announced that, yesterday, the MolDX Program ("MolDX") published a Future Effective Local Coverage Determination ("LCD") L39256, on molecular testing for esophageal precancer and cancer in Medicare beneficiaries, to become effective May 14, 2023. This foundational LCD, entitled "Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia" and published on CMS.gov, provides the criteria for future coverage of individual tests within this category, such as Lucid's EsoGuard® Esophageal DNA Test, following submission of each test for Technical Assessment.

Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer

PAVmed Inc. (PAVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

PAVmed Inc. (PAVM) Upgraded to Strong Buy: Here's What You Should Know

PAVmed Inc. (NASDAQ:PAVM ) Q4 2022 Earnings Conference Call March 15, 2023 8:30 AM ET Company Participants Michael Parks – Vice President, Investor Relations Lishan Aklog – Chairman and CEO Dennis McGrath – Chief Financial Officer Conference Call Participants Ross Osborn – Cantor Fitzgerald Frank Takkinen – Lake Street Capital Anthony Vendetti – Maxim Group Ed Woo – Ascendiant Capital Operator Welcome to the PAVmed's Business Update and Fourth Quarter 2022 Financial Results Conference Call. At this time all participants are in a listen-only mode.

PAVmed Inc. (PAVM) Q4 2022 Earnings Call Transcript

Conference call and webcast to be held tomorrow, March 15 th at 8:30 AM EST NEW YORK , March 14, 2023 /PRNewswire/ -- PAVmed Inc.  (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the year ended December 31, 2022. Conference Call and Webcast The webcast will be available at the investor relations section of the Company's website at pavmed.com.

PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results

NEW YORK, March 3, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Wednesday, March 15, 2023, at 8:30 AM EST. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's fourth-quarter 2022 financial results.

PAVmed to Hold a Business Update Conference Call and Webcast on March 15, 2023

Remote patient monitoring of first cohort of cancer patients using VerisBox™ connected devices and Veris CCP smartphone app initiated Cancer care team utilizing physiologic data and patient reported symptoms delivered to cloud-based Veris CCP clinician portal for real-time optimized personalized care NEW YORK , Feb. 28, 2023 /PRNewswire/ --  PAVmed Inc.  (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that the Veris Cancer Care Platform™ (Veris CCP), designed to enhance personalized cancer care through remote patient monitoring (RPM), is now live following successful onboarding of the first cohort of cancer patients and their clinicians. Enrolled patients received a VerisBox™ and were then successfully trained to use its Veris-branded Bluetooth-enabled connected health care devices to transmit real-time physiologic data to the cloud-based Veris CCP clinician portal via an embedded cellular connection.

PAVmed Digital Health Subsidiary Veris Health's Veris Cancer Care Platform™ Goes Live

PAVmed Inc. (PAVM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why PAVmed Inc. (PAVM) Looks Ripe for Bottom Fishing

NEW YORK--( BUSINESS WIRE )--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or “Lucid Diagnostics”), a commercial-stage cancer prevention diagnostics company, and Veris Health Inc. (“Veris”), a private digital health company focused on enhanced personalized cancer care, today provided a strategic business update, outlining near-term strategic priorities and resource reallocation. The companies will prioritize near-term Lucid and Veris Health commercialization efforts. They have implemented a workforce reduction of approximately 20 percent, product portfolio streamlining, and other cost-cutting measures which seek to lower quarterly cash burn by at least 25 percent.

PAVmed and Lucid Diagnostics Provide Strategic Business Update

NEW YORK--( BUSINESS WIRE )--PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD), a commercial-stage cancer prevention diagnostics company, and Veris Health Inc., a digital health company focused on enhanced personalized cancer care, today announced they will hold a joint conference call to provide a strategic business update on Tuesday, January 17, 2023 at 4:30PM EDT.

PAVmed and Lucid Diagnostics to Provide Strategic Business Update

NEW YORK--( BUSINESS WIRE )-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has entered into a license option and joint research and development agreement with Novosound Ltd. (“Novosound”), a venture-backed technology company based in Glasgow, Scotland, to explore applying Novosound's proprietary flexible thin-film ultrasound technology in medical imaging, initially targeting next-generation intravascular ultrasound (IVUS) imaging.

PAVmed Partners with Novosound on Ultrasound Imaging Technology

GLASGOW, Scotland--( BUSINESS WIRE )--Ultrasound sensor specialist Novosound has signed a commercial partnership agreement with PAVmed Inc., the Nasdaq-listed diversified medical technology company, to develop technology aimed at advancing intravascular imaging. The PAVmed agreement furthers Novosound's move into healthcare, and its regional expansion into North America.

News for PAVmed Stock (PAVM)